Approved uses
Allergic conjunctivitis, itching and redness
1 or 2 drops in the affected eye(s) up to 4 times daily, age 6 years and over
Cuts redness more than either component alone, and beats olopatadine 0.1% at 12 and 20 minutes post-challenge.
Contraindications
Sensitivity to naphazoline, pheniramine, or any component of the product.
Available FormsOphthalmic solution, 15 mL (0.5 fl oz) dropper bottle, 15 mL twin pack
Mechanism of ActionMixed alpha-1/alpha-2 adrenergic agonist (naphazoline) that constricts conjunctival vessels, combined with a first generation H1 antagonist (pheniramine) that blocks histamine-mediated itch. Decongestants with alpha-1 activity are associated with tachyphylaxis and rebound redness on repeated use, unlike the alpha-2 selective agonist brimonidine 0.025%.
Warnings & Precautions
- Rebound hyperemia: Chronic use can produce conjunctivitis medicamentosa; in a 70 patient case series of naphazoline, tetrahydrozoline or phenylephrine users, patterns were conjunctival hyperemia (50 cases), follicular conjunctivitis (17), and eczematoid blepharoconjunctivitis (3), with a median 4 weeks to resolution after discontinuation.
Pregnancy & Lactation
Pediatric Use